Qanatpharma (QP) is a Swiss clinical-stage biotech pioneering resistance artery medicine. Our Arteriome platform combines vascular biology, functional phenotyping and AI to discover novel drug targets and develop therapeutics for cardiovascular and neurological diseases.
Products, services, technology
LYRIC-HF: The Phase 2a study utilizes MRI & cognitive testing to quantify cerebral blood flow abnormalities, detect injury, cognitive and functional outcomes.
GENESIS-SAH (preclinical): aims to develop a life-saving therapy that restores cerebral auto-regulation to mitigate DCI after SAH.
Cooperation possibilities
QP seeks strategic partnerships with pharmaceutical and biotechnology companies for resistance-artery target discovery and validation using its Arteriome platform, clinical development and licensing of therapeutic assets, and joint research collaborations in cardiovascular & neurological diseases.
- https://www.qanatpharma.com/
- Send an email
- Christoph Meinert
